The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes.

Pediatric Transplantation
Vanessa FabrizioMichelle Hudspeth

Abstract

Hematopoietic stem cell graft cellular composition has been generally accepted to impact outcomes. Recent studies question this hypothesis. We conducted a single-center retrospective study of sixty-one pediatric BMT recipients for malignant (68%) and nonmalignant diseases (32%) examining effects of graft composition on engraftment, acute GVHD, chronic GVHD, and survival at day 100 and 1 year. Grafts contained a median of 3.63 x  08 TNC/kg (range: 0.031-10.31 x 108 TNC/kg) and 4.09 x 106 CD34+ /kg (range: 0.76-24.15 x 106 CD34+ /kg) with median neutrophil and platelet engraftment times of 17 and 29 days, respectively. A univariate analysis showed a trend for increasing TNC and increasing time to neutrophil engraftment HR: 0.875; CI: 0.075-1.001). Increasing CD34+ counts shortened time to platelet engraftment (HR: 1.085; CI: 1.015-1.161). No significant relationship was found between TNC, CD34+ , or CD3+ and acute or chronic GVHD. TNC or CD34+ did not affect day 100, 1-year survival, or 2-year survival. Increasing CD3+ counts demonstrated a negative trend on day 100 survival (HR: 1.108; CI: 1.001-1.036) but not 1-year survival or 2-year survival. These results add additional data questioning the effect of graft composition on out...Continue Reading

References

May 16, 2003·Bone Marrow Transplantation·S Heimfeld
Jun 28, 2003·Blood·Norbert C GorinUNKNOWN European Cooperative Group for Blood and Marrow Transplantation Acute Leukemia Working Party
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Aug 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nancy H CollinsDaniel J Weisdorf
Feb 23, 2010·Bone Marrow Transplantation·B E ShawUNKNOWN Ethics Working Group of the WMDA
Mar 17, 2010·Blood·Paul V O'DonnellUNKNOWN Donor Health and Safety Working Committee from Center for International Blood and Marrow Transplant Research (CIBMTR)
May 23, 2012·Bone Marrow Transplantation·M P HudspethD Ragucci
Feb 5, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Herbert PichlerGerhard Fritsch
Jun 4, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Johan TörlénMary Eapen
Feb 11, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mats RembergerJonas Mattsson
Aug 27, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Menachem BitanMichael A Pulsipher

❮ Previous
Next ❯

Citations

Apr 30, 2019·Journal of Pediatric Hematology/oncology·Trisha KissoonJohn Fort

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved